increased plasma IgM EndoCAb regardless of obesity status. sCD14 was not affected by diet, but LBP/sCD14 was lowered by yogurt consumption 23 in both YN and YO. Yogurt intervention increased plasma 2-arachidonoylglycerol in YO but not YN. YO peripheral blood mononuclear cells 24 expression of NF-κB inhibitor α and transforming growth factor β1 increased relative to CO at 9 weeks. Other biomarkers were unchanged by 25 diet. CO and YO gained approximately 0·9 kg in body weight. YO had 3·6 % lower diastolic blood pressure at week 3. Low-fat yogurt for 9 weeks 26 reduced biomarkers of chronic inflammation and endotoxin exposure in premenopausal women compared with a non-dairy control food. This 27 trial was registered as NCT01686204. 28 Key words: Obesity: Low-fat yogurt: Chronic inflammation: Endotoxin exposure: Dairy
29
Obesity is associated with increased risk of CVD, type 2 30 diabetes, hypertension and certain cancers (1) . These comor- 31 bidities are associated with chronic inflammation (1) . Unre- 32 solved, low-grade, obesity-associated inflammation originates 33 from the interplay between immune cells and metabolic tissues 34 such as adipose, liver, muscle, pancreas and brain in response 35 to excessive nutrient intake, leading to increased proin- 36 flammatory cytokine release (2) . Inflammation is exacerbated by 37 chronic endotoxin exposure resulting from compromised 38 intestinal barrier function in obese individuals (3, 4) . Endotoxin, 39 especially the gram-negative-derived lipopolysaccharide (LPS) 40 from gut microbiota, induces inflammation in humans (5) . LPS (TLR4)/MD2 complex (6) . The endocannabinoid (eCB) system 45 also modulates intestinal barrier function and metabolic endo-46 toxemia associated with obesity (4) . 47 Yogurt consumption appears to be a promising strategy to 48 improve obesity-associated intestinal barrier dysfunction and 49 prevent chronic inflammation. Consumption of containing yogurt reduced surrogate markers of endotoxemia 51 and decreased intestinal permeability in individuals with com-52 promised gut barrier integrity (7, 8) . Smaller intervention studies (14) . For the sample size calculation, an 8·2 % margin of error 111 for sCD14 was determined for a moderate group size (n 30/group) 112 based on the standard deviation of sCD14 in a prior study (14) . Table S1 . The baseline characteristics of participants are described in 240 50  1481  45  1402  59  1388  45  0·6579  LBP:sCD14  7·14  0·69  8·62  0·58  6·89  0·44  9·13  0·73 
CN, control non-obese; CO, control obese; YN, yogurt non-obese; YO, yogurt obese; WC, waist circumference; SysBP, systolic blood pressure; DiaBP, diastolic blood pressure; LPS, lipopolysaccharide; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14; IL-6, IL-6; hsCRP, high-sensitivity C-reactive protein; sTNF-RII, soluble TNF-receptor II; IgM EndoCAb, Ig M endotoxin-core antibody; AEA, anandamide; 2-AG, 2-arachidonoylglycerol. * Differences between obese and non-obese subjects were determined by independent t test (PROC TTEST).
obesity status had no effect on TNF-α or the TNF-α/sTNF-RII ratio. and YO (P treatment = 0·0052) ( Table 3 ). The primary study out-263 come, fasting plasma sCD14 was unchanged (Table 3) . Similarly, . The LBP/ 268 sCD14 ratio was lower in the yogurt consumption groups than in 269 the control groups (P treatment = 0·0477) (Table 3) . However, 0·08  0·89  0·11  0·4408  0·3934  0·6610  YN  0·88  0·13  0·87  0·10  CO  1·56  0·13  1·47  0·11  YO  1·86  0·22  1·59  0·19  hsCRP (mg/l)  CN  1·24  0·26  1·33  0·23  0·2670  0·5546  0·3711  YN  1·15  0·21  1·22  0·22  CO  2·97  0·31  2·98  0·32  YO  2·63  0·37  2·42  0·32  TNF 0·04  0·78  0·05  0·5334  0·1620  0·1565  YN  0·85  0·04  0·80  0·05  CO  1·15  0·06  1·03  0·06  YO  1·10  0·06  1·11  0·08  2-AG (nM)  C N  3 ·46  0·29  3·43  0·31  0·1188  0·7493  0·0372  YN  3·45  0·30  3·30  0·35  CO  4·60  0·33  3·74  0·32   a   YO  4·10  0·27  4·11  0·30 b CN, control non-obese; CO, control obese; YN, yogurt non-obese; YO, yogurt obese; hsCRP, high-sensitivity C-reactive protein; sTNF-RII, soluble TNF II; LPS, lipopolysaccharide; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14; IgM EndoCAb, Ig M endotoxin-core antibody; AEA, anandamide; 2-AG, 2-arachidonoylglycerol. a,b Mean values within a column with unlike superscript letters were significantly different (P < 0·05) by two-tailed t test. * The group difference at week 9 was compared by ANCOVA with baseline (week 0) as covariate (PROC GLM).
274
CO (P = 0·0114) ( Supplementary Fig. S1 ). After 9 weeks, YO NFKBIA 282 (encoding NF-κB inhibitor α (IκBα)) and encoding transforming 283 growth factor β1 (TGFB1) increased by 54 and 20 % from 284 baseline, respectively (Fig. 2) . In contrast, the mRNA expression 285 of these genes did not change in CO. 286 
Anthropometric changes

287
After 9 weeks intervention, BMI was affected by obesity status, 288 but not dietary treatment (P obesity = 0·0084) ( The present study demonstrated that consuming two servings of mechanism of chronic inflammation, particularly in obesity (3, 4) . The fold-change from baseline of target genes between groups was compared by independent t test. The difference between weeks 0 and 9 in each group was compared by paired t test. # P < 0·05, v. baseline in YO. $ P < 0·05, YO v. CO. TLR4, encoding Tolllike receptor 4; RELA, encoding p65 subunit of NF-κB; NFKBIA, encoding NF-? B inhibitor alpha; PTGS2, encoding cyclo-oxygenase-2, or COX-2; NCF1, encoding the p47 subunit of NADPH oxidase; IFNG, encoding interferon-γ; TGFB1, encoding transforming growth factor β1, or TGFβ. 
CN, control non-obese; CO, control obese; YN, yogurt non-obese; YO, yogurt obese; SysBP, systolic blood pressure; DiaBP, diastolic blood pressure. * The effects of treatment, obesity, and treatment × obesity were determined by two-factor repeated-measures ANOVA with time as a covariate (PROC MIXED).
leads to activation of the NF-κB pathway (22) Obesity is associated with subclinical endotoxemia which 326 increases chronic inflammation (5) . the difficulty of removing interference from the blood matrix (26) .
334
The LAL assay also does not account for lipoprotein-bound 335 LPS (27) . In addition, other bacterial compounds such as glyco- with plasma endotoxin (18, 19) . We observed that obese partici-360 pants had 27 % higher plasma LBP:sCD14 ratio than the non- CAb, which can bind to the inner core of endotoxin and protect 368 against endotoxin (30) . In a cross-sectional study involving 
377
Intestinal barrier function is regulated in-part by eCB. 2-AG 378 improves the intestinal barrier, whereas AEA is associated with 379 decreased intestinal barrier function (4) . barrier function and have anti-inflammatory properties (36, 37) .
447
Dairy product fermentation also liberates peptides with hypo-448 tensive activity, as reviewed elsewhere (6) . 
